Comparison of the real-world safety of two different long-acting methylphenidate formulations (Medikinet® MR and Concerta®) – a Danish nationwide register-based cohort study
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by Walter de Gruyter GmbH in Scandinavian Journal of Child and Adolescent Psychiatry and Psychology
- Vol. 12 (1) , 84-91
Abstract
Background: Medikinet® MR and Concerta® are long-acting methylphenidate formulations used for the treatment of pediatric and adult attention-deficit/hyperactivity disorder (ADHD). The two formulations have shown comparable safety profiles in two head-to-head randomized controlled trials. However, real-world studies comparing the safety profiles of these products are not available. Objective: This study aimed to compare the real-world safety of Medikinet® MR and Concerta® using register data. Method: This population-based cohort study was conducted based on data from Danish registries. The study included patients with continuous long-term (i.e., ≥12 months) exposure to either Medikinet® MR or Concerta® between 1995 and 2018. Outcomes included several selected adverse events of interest. A sensitivity analysis was performed, excluding patients exposed to Concerta® generics. For each outcome, Fisher’s exact test was performed to compare the number of cases between the two groups. Odds ratios (ORs) and 95% confidence intervals were estimated using logistic regression models with patients exposed to Concerta® as the reference group. Results: The study population included 1249 patients exposed to Medikinet® MR and 2455 patients exposed to Concerta®. No cases of cerebral arteritis or priapism were identified in either cohort. ORs for sudden death and anorexia could not be calculated due to the absence of cases in the Medikinet® MR cohort. For the remaining outcomes, no statistically significant difference in risk was found between Medikinet® MR-exposed and Concerta®-exposed patients. The sensitivity analysis produced results consistent with those obtained in the main analysis. Conclusions: The results of this population-based cohort study indicate that Medikinet® MR and Concerta® have comparable real-world safety profiles.Keywords
This publication has 36 references indexed in Scilit:
- Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adultsExpert Review of Pharmacoeconomics & Outcomes Research, 2013
- Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studiesBMC Psychiatry, 2013
- Stimulant Medication and Substance Use OutcomesJAMA Psychiatry, 2013
- The clinical impact of switching attention deficit hyperactivity disorder patients from OROS®-MPH to Novo-MPH ER-C®: A paediatric practice reviewPaediatrics & Child Health, 2013
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged AdultsJAMA, 2011
- ADHD Drugs and Serious Cardiovascular Events in Children and Young AdultsNew England Journal of Medicine, 2011
- Comparison of the Efficacy of Two Different Modified Release Methylphenidate Preparations for Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a Natural Setting: Comparison of the Efficacy of Medikinet ® Retard and Concerta ® —a Randomized, Controlled, Double-Blind Multicenter Clinical Crossover TrialJournal of Child and Adolescent Psychopharmacology, 2011
- The Danish Civil Registration SystemScandinavian Journal of Public Health, 2011
- European guidelines on managing adverse effects of medication for ADHDEuropean Child & Adolescent Psychiatry, 2010
- Long-acting medications for the hyperkinetic disordersEuropean Child & Adolescent Psychiatry, 2006